Doktor axborotnomasi 2025, № (117)
Maqola mavzusi
THE PROGNOSTIC SIGNIFICANCE OF HYPERURICEMIA AND GENE POLYMORPHISMS ENCODING UROMODULIN AND ANTIOXIDANT ENZYMES IN THE PROGRESSION OF CHRONIC KIDNEY DISEASE (98-103)
Mualliflar
E. N. Tashkenbayeva, M. O. Esankulov
Muassasa
Samarkand state medical university, Samarkand, Uzbekistan
Annotatsiya
Chronic kidney disease (CKD) is a global public health issue marked by progressive renal function decline, often exacerbated by hyperuricemia and genetic predispositions. Hyperuricemia is an independent risk factor for CKD progression, contributing to endothelial dysfunction, oxidative stress, and pro-fibrotic activity in renal tubular epitheli al cells. This study examines the prognostic significance of hyperuricemia and gene polymorphisms encoding uro modulin and antioxidant enzymes in CKD progression. A cohort of 333 patients with CKD stages 1–4 was analyzed to assess serum uric acid levels, genetic polymorphisms of uromodulin, superoxide dismutase (MnSOD), catalase (CAT), and glutathione peroxidase (GPX4). The study revealed significant correlations between hyperuricemia, GFR decline, and specific genetic variants. Multivariate analysis identified hyperuricemia, fasting glucose levels, and MnSOD gene polymorphisms as independent predictors of CKD progression. These findings underscore the im portance of early hyperuricemia management and genetic screening in personalized CKD treatment strategies.
Kalit so'zlar
chronic kidney disease, hyperuricemia, uromodulin, antioxidant enzymes, gene polymorphisms, glomer ular filtration rate.
Adabiyotlar
1. Pediatric Hyperuricemia Initiative Consortium. The Primary Hyperoxalurias and the Hyperuricosurias: Fatality, a Dent in Quality of Life, and Progress Globally. 2. Hyperuricemia is an independent predictor of mortality in cancer patients and is expected to network with different cancer-related signaling pathways. 3. Prevalence and risk factors associated with hyperuricemia in pediatric patients with stage 2-4 and 5 chronic kidney disease. 4. Allopurinol in Mild or Moderately Advanced Chronic Kidney Disease Patients with Marked Hyperuricemia: A Three-Year Outcome Trial. 5. LOD Score Testing for Molecular Evidence Supporting a Diagnosis of Familial Juvenile Hyperuricemic Nephrop athy.